Skip to content

Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis

MSgoesHome - Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04771858
Acronym
MSgoesHome
Enrollment
80
Registered
2021-02-25
Start date
2021-03-09
Completion date
2023-06-28
Last updated
2023-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Gait Analysis, Home-Monitoring

Brief summary

The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS). In a first step, the basic technical feasibility of measuring gait parameters in MS patients under standardized conditions in the clinic and in the home environment of the study participants will be investigated. In a subsequent two-week study phase, gait parameters (real-life monitoring) and standardized gait tests will be continuously recorded in the home environment of the study participants. The comparability of the collected gait parameters from standardized gait tests and real-life monitoring to clinical scales (e.g. EDSS) will investigate the medical applicability of gait analysis as a target parameter in MS patients. New algorithms for detecting indication-specific gait patterns from gait analysis in patients' daily lives and their possible changes over time (progression) will be explored and implemented into the study system. In addition, a patient app annotates the standardized gait tests and collects questionnaire-based data from the study participants during real-life monitoring. Via a study tablet, the data of the gait analysis and the patient app are transmitted to a study platform (Digital Patient Manager). The clinical assessment data (neurological examination, questionnaires) can be entered via a web front-end of the study platform and assigned to the patient via a pseudonym. A further aim of this study is to validate the technology used for its applicability in the home environment. By means of structured interviews after the study phase, the study participants will be asked about compliance and adherence. The following scientific questions will be investigated in this project: (a) Is gait analysis a feasible and meaningful target parameter for MS centers? b) Are gait parameters from real-life monitoring suitable biomarkers for the detection of MS symptoms? c) Can gait parameters from standardized gait tests be compared with different testing environments (clinic / home environment)? d) How do gait parameters from standardized gait tests differ from gait data from real-life monitoring? e) How is the telemedical application for the collection of gait parameters evaluated by the patients? f) Can disease progression be detected using sensor-based gait parameters from the home environment?

Interventions

None listed

Sponsors

Celgene Corporation
CollaboratorINDUSTRY
NeuroSys GmbH
CollaboratorUNKNOWN
Fraunhofer Institute for Integrated Circuits IIS
CollaboratorUNKNOWN
Portabiles HealthCare Technologies GmbH
CollaboratorUNKNOWN
University of Regensburg
CollaboratorOTHER
Medical Valley Digital Health Application Center GmbH
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of multiple sclerosis according to McDonald criteria * Expanded Disability Status Scale (EDSS) 1-6 * Age \> 18 years * Ability to speak and read * Ability to use an application running on a smart device * Patient informed consent

Exclusion criteria

* Severe difficulty walking with frequent falls * Inability to walk at least 10 meters * Permanent use of a wheelchair * Severe spasticity * Cognitive impairment with inability to give consent to protocol

Design outcomes

Primary

MeasureTime frameDescription
System Usability Scale (SUS)day 14 (closeout visit)SUS score per patient - range from 0 to 100 score points (Higher scores mean a better outcome.)
Number of detected gait cycles per patient per dayday 1 to day 14Number of sensor-detected gait cycles (one gait cycle are two steps) per patient per day
Daily sensor wear time per patientday 1 to day 14Percentage of sensor wear time per patient per day - range from 0 hours (0%) to 6 hours (100%)
Completeness of days during 14-day field period per patient with sensor recordsday 1 to day 14Percentage of days with sensor data recorded per patient - range from 0 days (0%) to 14 days (100%)

Secondary

MeasureTime frameDescription
Difference in time of 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinicday 1Difference in time, measured in seconds, of 25FWT performed at home and performed at clinic
Difference in gait parameters during 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinicday 1Difference in gait parameters (gait length in cm, speed in m/s, contact angle in degree, swing-through phase in percent, standing phase in percent, lateral swing in cm, toe clearance in cm, lifting angle of toes in cm, impact intensity in g, variability of these parameters and symmetry between left and right foot) during 25FWT performed at home versus 25FWT performed at clinic
Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at homeday 1 and day 14Correlation of change of EDSS (range from 0.0 to 10.0, Lower scores mean a better outcome.) and change of time to execute 25FWT in seconds performed at home
Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at clinicday 1 and day 14Correlation of change of EDSS (range from 0.0 to 10.0, Lower scores mean a better outcome.) and change of time to execute 25FWT in seconds performed at clinic

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026